Topic	Questions
Usual practice	Before we get into the specifics, I’m interested in understanding how repeat medications are reviewed in your practice. (How often, within/outside of consultations, patient involvement, purpose, barriers, facilitators?) Can you tell me about your experience of reviewing medications for patients with polypharmacy? (Different from other medication reviews?) Do pharmacists play a role in medication reviews in your practice? (CCG pharmacist or practice pharmacist?) Are any other non-GP staff involved in medication reviews in your practice?
Usual practice case patients	Can you think of any non-3D patients who are prescribed lots of medications, whom you could look up on EMIS? Could you talk through how you might review their medications? (Is that typical?)
3D Study	I’d like to ask you to focus more on the 3D Study now. How have you found reviewing patients’ medications during the 3D consultations? (Purpose of the reviews; pharmacist recommendations, patient involvement, types of changes made, examples.)
3D Study case patients (2–3 for each interview)	Can you have a read over the record for this patient and talk me through how you might have come to the decisions about their medications? (Changes made; pharmacist recommendations — looked at, useful, acted on, concerns; patient involvement; typical of other reviews; same as/different from usual practice.)
Any other issues	Any other issues you would like to raise?

3D Study = a multicentre, cluster-randomised controlled trial of an organisational intervention for people with multimorbidity.¹⁹ CCG = clinical commissioning group EMIS = Egton Medical Information Systems.